12/7 2023

MTEC member SurgiBox Inc.’s product recognized as a best invention by Time Magazine

2024-02-02T08:22:24-05:00December 7th, 2023|Success Stories|

MTEC member and small business SurgiBox Inc. is an inventor of surgical kits that allow doctors to perform life-saving surgeries anywhere – even in the middle of war zones or other hostile situations.

11/15 2023

Inhalon Biopharma secures U.S. Army Medical Research and Development Command award to support development of inhaled therapeutics for treatment of COVID-19

2024-02-02T08:22:25-05:00November 15th, 2023|ATI in the News|

Inhalon Biopharma, a clinical-stage company advancing a proprietary inhaled antibody platform for treating acute respiratory infections (ARI), today announced that it has been awarded a $5.7 million contract by the U.S Army Medical Research and Development Command (USAMRDC) to support a U.S. Army Military Performance Advancement Initiative (MPAI) project to develop new treatments for COVID-19 and other SARS infections.

7/20 2023

MTEC members awarded to advance treatments for repeated mild traumatic brain injury

2024-02-02T08:22:45-05:00July 20th, 2023|Success Stories|

Astrocyte Pharmaceuticals and the University of Kentucky (partnered with Mitochon Pharmaceuticals) are working diligently to advance the development of drug treatments for repeated mild traumatic brain injury (mTBI).  Each received $500,000 awards co-funded by the Medical Technology Enterprise Consortium and BrightFocus Foundation to support preclinical studies, preparation for clinical studies, and submission of an IND application.

4/4 2023

Army R&D selects biotech firm to prevent wound infection

2024-02-02T08:22:48-05:00April 4th, 2023|ATI in the News|

The award is part of the Military Prototype Advancement Initiative, funded by the Department of Defense and issued through the Medical Technology Enterprise Consortium, a collaboration of industry and academia to facilitate R&D activities with USAMRDC and other government agencies.

2/9 2023

Vivacelle Bio’s VBI-S Phase IIa clinical trial meets primary and secondary endpoints for treating hypovolemia in septic shock patients

2024-02-02T08:23:10-05:00February 9th, 2023|ATI in the News|

Vivacelle Bio, Inc., a privately held life science company focused on the development of treatments for hypovolemia in shock including septic shock and hemorrhagic shock, announced the successful completion of its Phase IIa clinical trial of VBI-S in septic shock patients with severe hypovolemia.

8/11 2022

Medical Innovation Challenge announces contenders for $200,000 award

2024-02-02T08:23:31-05:00August 11th, 2022|Press Releases|

Advanced Technology International (ATI) and TechConnect today announced 25 finalists who will pitch on September 28, 2022 at Defense TechConnect Innovation Summit for $200,000 in non-dilutive awards. These candidates receive membership from four consortia with a combined $50B in federal contracting authority including: Medical CBRN Defense Consortium (MCDC), Countering Weapons of Mass Destruction Consortium (CWMD), Medical Technology Enterprise Consortium (MTEC), and Senior Healthcare Innovation Consortium (SHIC).

Go to Top